Guidance on the management of adverse reactions induced by poly(ADP-ribose) polymerase inhibitors.
10.3724/zdxbyxb-2022-0284
- Author:
Of Zhejiang Medical Association SOCIETY OF OBSTETRICS AND GYNECOLOGY
;
Of Zhejiang Medical Association SOCIETY OF UROLOGY
;
Of Zhejiang Anticancer Association COMMITTEE OF BREAST CANCER
;
Of Zhejiang Anticancer Association Preparation COMMITTEE OF CLINICAL PHARMACY ON ONCOLOGY
;
Of Zhejiang Society For Mathematical Medicine COMMITTEE OF UROLOGY
- Publication Type:Journal Article
- Keywords:
Adverse reaction;
Clinical management;
Expert opinion;
PARP;
Poly (ADP-ribose) polymerase inhibitors
- MeSH:
Humans;
Poly(ADP-ribose) Polymerase Inhibitors/adverse effects*;
Phthalazines/pharmacology*;
Poly(ADP-ribose) Polymerases;
Fatigue/drug therapy*
- From:
Journal of Zhejiang University. Medical sciences
2023;51(6):765-774
- CountryChina
- Language:English
-
Abstract:
The common adverse reactions caused by poly (ADP-ribose) polymerase (PARP) inhibitors include hematological toxicity, gastrointestinal toxicity and fatigue. The main prevention and treatment of hematological toxicity include: regular blood tests, referral to hematology department when routine treatment is ineffective, and being alert of myelodysplastic syndrome/acute myeloid leukemia. The key points to deal with gastrointestinal toxicity include: taking medicine at the right time, light diet, appropriate amount of drinking water, timely symptomatic treatment, prevention of expected nausea and vomiting, and so on. For fatigue, full assessment should be completed before treatment because the causes of fatigue are various; the management includes massage therapy, psychosocial interventions and drugs such as methylphenidate and Panax quinquefolius according to the severity. In addition, niraparib and fluzoparib can cause hypertension, hypertensive crisis and palpitation. Blood pressure and heart rate monitoring, timely symptomatic treatment, and multidisciplinary consultation should be taken if necessary. When cough and dyspnea occur, high resolution CT and bronchoscopy should be performed to exclude pneumonia. If necessary, PARP inhibitors should be stopped, and glucocorticoid and antimicrobial therapy should be given. Finally, more attention should be paid to drug interaction management, patient self-management and regular monitoring to minimize the risk and harm of adverse reactions of PARP inhibitors.
